2026-08-08

Encompass Health (EHC) Stock Jumps 13% on Q2 Beat - Rehab Hospital Operator Raises 2026 Guidance for Second Straight Quarter

Written & reviewed by the TradeSmrt editorial team · 2026-08-08

In this article

What Happened
What's Behind the Number - Patient Volume and Revenue Per Patient Both Rose
Why a Second Straight Guidance Raise Matters
A Sector Full of Split Reactions
What to Take Away From This
Sources

What Happened

Over August 5-6, Encompass Health (NYSE: EHC), the largest operator of inpatient rehabilitation hospitals in the United States, reported second-quarter 2026 results. Net operating revenue came in at $1.597 billion, up 9.6% from $1.548 billion a year earlier, while non-GAAP diluted earnings per share reached $1.55, up 10.7% from $1.40 and 4.7% above the analyst consensus. Adjusted EBITDA grew nearly in lockstep, rising 9.2% year-over-year, which kept the adjusted EBITDA margin steady at roughly 21.8%. Because revenue and profit grew at almost the same pace and both cleared Wall Street's bar, this read as an unusually clean, balanced beat rather than a quarter propped up by one metric alone.

The market reacted fast and hard. Shares jumped 13.2% in the afternoon session on the day results crossed the wire, and by the close on August 6 the stock was up 12.6% for the day to $124.82. Over the trailing week, the stock climbed roughly 12.75% to around $125. Relative to the broader market and to other healthcare names reporting this earnings season, the move stood out.

What's Behind the Number - Patient Volume and Revenue Per Patient Both Rose

The most notable part of this report is the quality of the growth. Encompass Health's second-quarter discharges totaled 68,895, up 5.6% year-over-year, while net patient revenue per discharge rose an additional 3.9% on top of that. In other words, the growth came from both more patients moving through the system (a volume effect) and higher revenue collected per patient (a pricing/mix effect) at the same time - not from leaning on just one lever. That combination is part of why the market treated the beat as a durable signal rather than a one-off.

Operating metrics reinforced the same picture. Occupancy reached 77.4%, and average daily census topped 9,000 patients for the first time in company history - in both the first and second quarters of the year. The company also disclosed quality-of-care metrics: 84.7% of patients were discharged back to the community, 8.4% were transferred to an acute-care hospital, and 6.1% went to a skilled nursing facility. CEO Mark Tarr said on the earnings call that "our performance on each of these quality metrics continues to exceed industry averages." In the inpatient rehabilitation business, these discharge-outcome figures aren't just a footnote - they feed directly into physician and insurer referral patterns, which makes them something close to a leading indicator for future patient volume.

Why a Second Straight Guidance Raise Matters

Encompass Health also raised its full-year 2026 outlook again in this release. The company now expects net operating revenue of $6.41-$6.49 billion, adjusted EBITDA of $1.365-$1.395 billion, and adjusted EPS of $6.02-$6.25. This marks the second time this year the company has lifted its guidance. Back at its first-quarter report in late April/early May, Encompass Health had already raised its outlook to $6.375-$6.470 billion in revenue and $5.89-$6.11 in adjusted EPS - and this quarter's release pushed that range higher still. On the call, Tarr said the company was "again raising our guidance for 2026" based primarily on the second-quarter results.

A guidance raise that repeats quarter after quarter carries a different meaning for investors than a single upward revision - it reads as a trend rather than a lucky quarter. And the growth underlying this trend isn't a one-time event: it's tied to a structural capacity-expansion plan. The company said it plans to open seven new hospitals this year and add another 100-150 beds to existing facilities. Because inpatient rehabilitation is a capital-intensive business where physical bed count sets a hard ceiling on revenue, newly opened hospitals and added beds tend to show up in revenue growth over the following several quarters in a fairly predictable, trackable way. This guidance raise, in that sense, reflects both beds that are already open ramping toward full occupancy and a visible pipeline of additional beds still to come online.

A Sector Full of Split Reactions

The contrast with other healthcare earnings covered on this site this week is striking. Dialysis provider DaVita (DaVita Stock Falls 18%) beat both EPS and revenue estimates last week, yet shares plunged nearly 18% in a single day after softening revenue-per-treatment and unchanged guidance overshadowed the headline beat. Sleep-apnea device maker ResMed (ResMed Falls 5%) also beat on both revenue and EPS, but its first-ever fiscal 2027 guidance came in below the market's recent trend, and shares fell more than 5%. In both cases, a solid quarter collided with a forward-looking signal the market read as negative, and the stock reaction followed the signal, not the quarter that had just closed.

Encompass Health sits at the exact opposite end of that spectrum. Revenue and earnings beat consensus, the composition of that growth (volume plus pricing, moving together) looked durable, and the forward-looking signals - a second consecutive guidance raise and a concrete bed-expansion pipeline - all pointed the same direction. With every piece of the story aligned, the stock didn't hesitate to reflect it. Taken together, these three healthcare reports make the same underlying point: whether a company "beat earnings" tells you far less about where the stock goes than what that beat implies about the next several quarters.

What to Take Away From This

Growth built on both volume and price tends to earn more trust than growth from either alone. When patient counts (or unit volume, more broadly) and revenue per unit both rise together, as they did here, that combination signals more durability than a beat driven by a single lever. When reading any earnings report, it's worth separating out how much of the revenue growth came from volume versus price/mix.
The frequency of guidance raises is itself a signal. A single upward revision can be noise; a raise that repeats across consecutive quarters is more often read by the market as a genuine trend.
In capital-intensive industries, watch the physical capacity pipeline. In sectors like hospitals, factories, or data centers where physical infrastructure sets the ceiling on revenue, publicly disclosed plans for new facility openings or capacity additions can serve as a forward-looking gauge of the next several quarters' growth potential.
The same sector and the same "beat" can produce opposite stock reactions. Placing DaVita, ResMed, and Encompass Health side by side shows that it's the forward-looking signal embedded in an earnings report - not simply whether it beat estimates - that tends to drive the size and direction of the stock's move.

Sources

This article synthesizes and analyzes the reporting below in our own words - it is not a reproduction of the original text. For the latest figures and full detail, please refer to the original sources.

⚠️ This article is for informational purposes only and is not investment advice. Market conditions change constantly - always verify the latest data yourself before making any investment decision.